Advertisement

Topics

BARCLAYS Company Profile

07:17 EDT 24th June 2018 | BioPortfolio

Nil

Contact

Email: internetsecurity@barclays.co.uk


News Articles [132 Associated News Articles listed on BioPortfolio]

Barclays Appoints Todd Sandoz as Head of Equities, Americas

Barclays today announces the appointment of Todd Sandoz as Head of Equities, Americas, based in New York. Mr. Sandoz will lead Barclays' Americas Equities business across Cash, Derivatives (inclus...

Investors feast on Just Eat as Barclays comes back for another serving

Barclays analyst Gerardus Vos thinks revenue momentum is building on the back of a successful marketing campaign, while he also believes Just Eat’s stake in a Brazilian firm is undervalued

Barclays belässt Novartis auf 'Underweight' - Ziel 80 Franken

Die britische Investmentbank Barclays hat die Einstufung für Novartis vor dem Hintergrund der noch laufenden Dermatologie-Konferenz AAD in San Diego auf "Underweight" mit einem Kursziel von 80 Fra...

Barclays belässt GlaxoSmithKline auf 'Overweight'

Die britische Investmentbank Barclays hat die Einstufung für GlaxoSmithKline auf "Overweight" mit einem Kursziel von 1650 Pence belassen. Analyst Emmanuel Papadakis begrüßte in einer am Montag vor....

Achillion Pharmaceuticals (ACHN) Upgraded to "Hold" by Barclays

The firm currently has a $5.00 price objective on the biopharmaceutical company's stock. Barclays' target price points to a potential upside of 35.14% from the stock's previous close.

Barclays belässt Sanofi auf 'Underweight' - Ziel 65 Euro

Die britische Investmentbank Barclays hat die Einstufung für Sanofi vor dem Hintergrund der noch laufenden Dermatologie-Konferenz AAD in San Diego auf "Underweight" mit einem Kursziel von 65 Euro ...

Barclays hebt Ziel für Nike auf 80 US-Dollar - 'Overweight'

Die britische Investmentbank Barclays hat das Kursziel für die Aktien des Sportartikelherstellers Nike von 75 auf 80 US-Dollar angehoben und die Einstufung auf "Overweight" belassen. Dies geht aus...

Barclays belässt Bayer auf 'Underweight' - Ziel 95 Euro

Die britische Investmentbank Barclays hat die Einstufung für Bayer vor einer Investorenveranstaltung zum europäischen Gesundheitsmarkt auf "Underweight" mit einem Kursziel von 95 Euro belassen. Di.....

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [4 Associated Companies listed on BioPortfolio]

BARCLAYS

Nil

Esay Solutions

eSAY develop answers for business problems. As a complete IT consultancy, we offer our clients the opportunity to improve their business through the application of tailored IT products. We have helped...

hblmedia

hbl media is a fast growing, London-based communications agency that specialises in helping companies and organisations to communicate their brand values through the media.Our approach to communicatio...

Veracode

Veracode is the only independent provider of cloud-based application intelligence and security verification services. The Veracode platform provides the fastest, mos...

More Information about "BARCLAYS" on BioPortfolio

We have published hundreds of BARCLAYS news stories on BioPortfolio along with dozens of BARCLAYS Clinical Trials and PubMed Articles about BARCLAYS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BARCLAYS Companies in our database. You can also find out about relevant BARCLAYS Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record